{"prompt": "['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'D-Code Assigned by AstraZeneca', \"The investigator's name and address\", 'The Protocol Title and AstraZeneca ESR reference number', 'Causality of event(s)', '* Investigative site must also indicate, either in the SAE report or the cover page, the causality', 'of events in relation to all study medications and if the SAE is related to disease progression,', 'as determined by the Principal Investigator.', '* Send SAE re ort and accom an in cover a eb wa o Email to', 'If a non-serious AE becomes serious, this and other relevant follow-up information must also', 'be provided to AstraZeneca.', 'Serious adverse events that do not require expedited reporting, still need to be reported to', 'AstraZeneca preferably using the MedDRA coding language for serious adverse events. This', 'information should be reported on a monthly basis and under no circumstance less frequently', 'than quarterly.', 'All SAEs have to be reported to AstraZeneca, whether or not considered causally related to', 'the investigational product. All SAEs will be documented. The investigator is responsible for', 'informing the IRB and/or the Regulatory Authority of the SAE as per local requirements.', 'Non-serious adverse events and SAEs will be collected from the time consent is given,', 'throughout the treatment period and up to and including the 30 day follow-up period. After', 'withdrawal from treatment, subjects must be followed-up for all existing and new AEs for 30', 'calendar days after the last dose of trial drug and/or until event resolution. All new AEs', 'occurring during that period must be recorded (if SAEs, then they must be reported to', 'AstraZeneca). All study-related toxicities/ SAEs must be followed until resolution, unless in', \"the Investigator's opinion, the condition is unlikely to resolve due to the patient's underlying\", 'disease.', '6.2.9', 'Laboratory safety assessment', 'Full hematology assessments for safety (hemoglobin, red blood cells [RBC], platelets, mean', 'cell volume [MCV], mean cell hemoglobin concentration [MCHC], mean cell hemoglobin', '[MCH], white blood cells [WBC], absolute differential white cell count (neutrophils,', 'lymphocytes, monocytes, eosinophils and basophils) and absolute neutrophil count or', 'segmented neutrophil count and Band forms should be performed at each visit and when', 'clinically indicated. If absolute differentials not available please provide % differentials.', 'Coagulation [activated partial thromboblastin time (APTT) and international normalized ratio', '53(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', '[17] will be performed at baseline and if clinically indicated unless the patient is receiving', 'warfarin.', 'Biochemistry assessments for safety (sodium, potassium, calcium, magnesium, fasting', 'glucose, creatinine, total bilirubin, gamma glutamyltransferase [GGT], alkaline phosphatase', '[ALP], aspartate transaminase [AST], alanine transaminase [ALT], urea or blood urea', 'nitrogen [BUN], total protein, albumin and lactic dehydrogenase [LDH]).', 'Urinalysis by dipstick should be performed at baseline and then only if clinically indicated.', \"Microscopic analysis should be performed by the hospital's local laboratory if required.\", 'Bone marrow or blood cytogenetic samples may be collected for patients with prolonged', 'hematological toxicities as defined in Section 8.2.7.', \"These tests will be performed by the hospital's local laboratory. Additional analyses may be\", 'performed if clinically indicated.', 'Any clinically significant abnormal laboratory values should be repeated as clinically', 'indicated and recorded on the eCRF.', 'In case a subject shows an AST or ALT >3xULN or total bilirubin > 2xULN please refer to', 'Appendix 1 \"Actions required in cases of combined increase of Aminotransferase and Total', \"Bilirubin - Hy's Law', for further instructions\", 'For blood volume see Section 7.1.', '6.2.10', 'Physical examination', 'Physical examinations will occur as outline in Sections 5.2 and 5.3. Organ systems to be', \"assessed will be based on the treating clinician's medical judgment.\", '6.2.11', 'ECG', 'ECGs are required within 7 days prior to starting study treatment and when clinically', 'indicated.', 'Twelve-lead ECGs will be obtained after the patient has been rested in a supine position for at', 'least 5 minutes in each case. The Investigator or designated physician will review the paper', 'copies of each of the timed 12-lead ECGs on each of the study days when they are collected.', 'ECGs will be recorded at 25 mm/sec. All ECGs should be assessed by the investigator as to', 'whether they are clinically significantly abnormal / not clinically significantly abnormal. If', 'there is a clinically significant abnormal finding, the Investigator will record it as an AE on', 'the eCRF. The original ECG traces must be stored in the patient medical record as source', 'data.', '54(93)', 'Printed on 3/25/202']\n\n###\n\n", "completion": "END"}